## THERMO ELECTRON CORP

## Form 8-K

April 27, 2005

$$
\begin{gathered}
\text { UNITED STATES } \\
\text { SECURITIES AND EXCHANGE COMMISSION } \\
\text { Washington, D.C. } 20549 \\
\text { FORM 8-K } \\
\text { CURRENT REPORT } \\
\text { Pursuant to Section } 13 \text { or } 15 \text { (d) of } \\
\text { the Securities Exchange Act of } 1934 \\
\text { Date of Report } \\
\text { (Date of earliest event } \\
\text { reported): } \\
\text { April } 27,2005
\end{gathered}
$$

Delaware $\quad$ 1-8002
(State or other jurisdiction of
incorporation or organization) $\quad$ (Commission File Number)
(State or other jurisdiction of
(Commission File Number)
incorporation or organization)

81 Wyman Street, P.O. Box 9046
Waltham, Massachusetts
(Address of principal executive offices)
(781) 622-1000
(Registrant's telephone number including area code)

This Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading "Forward Looking Statements" in the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2004. These include risks and uncertainties relating to the need to develop new products and adapt to significant technological change, dependence on customers that operate in cyclical industries, general worldwide economic conditions and related uncertainties, the effect of changes in governmental regulations, dependence on customers' capital spending policies and government funding policies, use and protection of intellectual property, exposure to product liability claims in excess of insurance coverage, retention of contingent liabilities from businesses we sold, realization of potential future savings from new productivity initiatives, implementation of our branding strategy, implementation of strategies for improving internal growth, the effect of exchange rate fluctuations on international operations, identification,
completion and integration of new acquisitions and potential impairment of goodwill from previous acquisitions. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Item 2.02 Results of Operations and Financial Condition.
On April 27, 2005, the Registrant announced its financial results for the fiscal quarter ended April 2, 2005. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information contained in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.
(c) Exhibits

The following Exhibit relating to Item 2.02 shall be deemed "furnished", and not "filed":
99.1 Press Release dated April 27, 2005.

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 27 th day of April, 2005.

THERMO ELECTRON CORPORATION

By: /s/ Peter E. Hornstra
Peter E. Hornstra
Corporate Controller and Chief
Accounting Officer

```
FOR IMMEDIATE RELEASE
Media Contact Information:
Lori Gorski
Phone: 781-622-1242
E-mail: lori.gorski@thermo.com
Website: www.thermo.com
```

Investor Contact Information:
J. Timothy Corcoran

Phone: 781-622-1111
E-mail: tim.corcoran@thermo.com
$\qquad$

> Thermo Electron Reports $15 \%$ Growth in Earnings per Share in First Quarter 2005 and Raises Guidance for Full Year

WALTHAM, Mass., April 27, 2005 - Thermo Electron Corporation (NYSE:TMO) today reported revenues of $\$ 559$ million for the first quarter of 2005 , a 7 percent increase from $\$ 525$ million in 2004 . The revenue increase results from the effect of acquisitions (5\%) and currency translation (2\%). GAAP diluted earnings per share (EPS) grew 15 percent in the 2005 quarter to $\$ .30$, compared with $\$ .26$ in the year-ago period. GAAP operating income rose 13 percent in 2005, and GAAP operating margin increased to 10.7 percent from 10.1 percent in 2004.

Adjusted EPS also grew 15 percent, to $\$ .31$ in the first quarter of 2005, compared with $\$ .27$ in the 2004 quarter. Adjusted operating income increased 7 percent to record first quarter levels since the company's reorganization in 2000. Adjusted operating margin was 11.9 percent in both periods.

Adjusted EPS, adjusted operating income and adjusted operating margin are non-GAAP measures that exclude certain items detailed at the end of this press release under the heading, "Use of Non-GAAP Financial Measures."

First Quarter Highlights

| 0 | EPS grew 15 percent |
| :--- | :--- |
| 0 | More than 20 new products introduced at Pittcon |
| 0 | Signed agreement to acquire Kendro Laboratory Products |
| O Acquired Niton, a provider of portable industrial X-ray analyzers, at |  |
| quarter end |  |
| Acquired R\&P, a supplier of air-quality monitoring instruments, after |  |
| quarter end |  |

"We are pleased to report another quarter of solid bottom-line growth, with a 15 percent increase in EPS," said Marijn E. Dekkers, president and chief executive officer of Thermo Electron. "We are consistently growing earnings despite the weaker conditions we've recently faced in some of our end markets, most notably pharmaceutical, offset by strength in industrial segments.

[^0]2005, resulting in adjusted EPS guidance of $\$ .32$ to $\$ .34-\mathrm{a} 10$ to 17 percent increase over $\$ .29$ in the 2004 quarter. For the full year, we are raising our previous estimate of $\$ 1.40$ to $\$ 1.45$ to our new guidance of $\$ 1.42$ to $\$ 1.47$, which is 14 to 18 percent higher than last year's \$1.25." (This guidance excludes approximately $\$ .04$ of expense per quarter from the amortization of acquisition-related intangible assets; it also excludes results from the pending Kendro acquisition and the other items described in this press release under the heading, "Use of Non-GAAP Financial Measures.")

## Life and Laboratory Sciences

The Life and Laboratory Sciences segment reported an 8 percent revenue increase in the first quarter of 2005 to $\$ 393$ million, versus $\$ 365$ million in the 2004 quarter. GAAP operating income for the segment grew 11 percent in the 2005 quarter, with GAAP operating margin increasing to 13.2 percent from 12.8 percent a year ago. Adjusted operating income increased 6 percent in the 2005 period, and adjusted operating margin was 14.4 percent, compared with 14.7 percent in 2004 .

Measurement and Control
First quarter revenues in the Measurement and Control segment grew 4 percent to $\$ 166$ million in the first quarter of 2005 , compared with $\$ 160$ million a year ago. GAAP operating income for the segment increased 29 percent in the 2005 quarter, and GAAP operating margin rose to 11.1 percent from 8.9 percent last year. Adjusted operating income grew 25 percent in the 2005 period, and adjusted operating margin increased to 12.2 percent, versus 10.1 percent in 2004.

Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude restructuring and other costs/income and amortization of acquisition-related intangible assets. Adjusted EPS and adjusted operating income also exclude certain other gains and losses, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards and the impact of the resolution of significant tax audits. In addition, our adjusted EPS guidance excludes results of pending acquisitions and the impact of accounting principles not yet adopted. We exclude these
items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the inclusion of such measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts.

Specifically:
We exclude costs and tax effects associated with restructuring activities, such as reducing overhead and consolidating facilities, in connection with the final phase of our overall reorganization, which we substantially completed in 2004. We believe that the costs related to these restructuring activities are not indicative of our normal operating costs.

We exclude charges relating to the sale of inventories revalued at the date of acquisition, as we believe these charges are not indicative of our normal operating costs.

We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of 5 to 10 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

We also exclude certain gains/losses and related tax effects, benefits from tax credit carryforwards and the impact of the resolution of significant tax audits, which are either isolated or cannot be expected to occur again with any regularity or predictability and that we believe are not indicative of our normal operating gains and losses. We exclude gains/losses from the sale of our equity interests in Newport Corporation and Thoratec Corporation, as well as other items such as the sale of a business or real estate and the early retirement of debt.

Thermo's management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company's core operating performance and comparing such performance to that of prior periods and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes.

The non-GAAP financial measures of Thermo's results of operations included in this press release are not meant to be considered superior to or a substitute for Thermo's results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables. Thermo's earnings guidance, however, is only provided on an adjusted basis. It is not feasible to provide GAAP EPS guidance because the items excluded, other than the amortization expense, are difficult to predict and estimate and are primarily dependent on future events, such as the timing of completion of and results from pending acquisitions, the impact of accounting principles not yet adopted, decisions concerning the location and timing of facility consolidations and the timing of and proceeds from the sale of our equity interests in Newport and Thoratec. We no longer own any shares of FLIR Systems.

## Conference Call

Thermo Electron will hold its earnings conference call today, April 27, at 9:00 a.m. Eastern time. To listen, dial 888-872-9028 within the U.S., or 973-633-6740 outside the U.S. You may also listen to the call live on the Web by visiting http://www.thermo.com. Click on "About Thermo," then "Investors." An audio archive of the call will be available in that section of our Web site until Friday, May 27, 2005. You will also find this press release, including the accompanying reconciliation of non-GAAP financial measures, under the heading "Press Releases," and related information under the heading "Financial Reports," in the Investors section of our Web site.

About Thermo Electron

Thermo Electron Corporation is the world leader in analytical instruments. Our instrument solutions enable our customers to make the world a healthier, cleaner and safer place. Thermo's Life and Laboratory Sciences segment provides analytical instruments, scientific equipment, services and software solutions for life science, drug discovery, clinical, environmental and industrial laboratories. Thermo's Measurement and Control segment is dedicated to providing analytical instruments used in a variety of manufacturing processes and in-the-field applications, including those associated with safety and homeland

# Edgar Filing: THERMO ELECTRON CORP - Form 8-K 

security. Based near Boston, Massachusetts, Thermo has revenues of more than $\$ 2$ billion, and employs approximately 10,000 people in 30 countries. For more information, visit http://www.thermo.com.

The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading "Forward-Looking Statements" in the company's Annual Report on Form $10-\mathrm{K}$ for the fiscal year ended December 31, 2004. These include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change, dependence on customers that operate in cyclical industries, general worldwide economic conditions and related uncertainties, the effect of changes in governmental regulations, dependence on customers' capital spending policies and government funding policies, use and protection of intellectual property, exposure to product liability claims in excess of insurance coverage, retention of contingent liabilities from businesses we sold, realization of potential future savings from new productivity initiatives, implementation of our branding strategy, implementation of strategies for improving internal growth, the effect of exchange rate fluctuations on international operations, identification, completion and integration of new acquisitions and potential impairment of goodwill from previous acquisitions. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Consolidated Statement of Income (unaudited)

| (In thousands except per share amounts) | April 2, 2005 |  |
| :---: | :---: | :---: |
|  | Reported (a) | Adjusted (b) |
| Revenues | \$ 559,208 | \$ 559,208 |
| Costs and Operating Expenses: |  |  |
| Cost of revenues (c) | 299,974 | 299,974 |
| Selling, general and administrative expenses | 156,087 | 156,087 |
| Amortization of acquisition-related intangible assets | 7,414 | - |
| Research and development expenses | 36,328 | 36,328 |
| Restructuring and other costs (income), net (d) | (271) | - |
|  | 499,532 | 492,389 |
| Operating Income | 59,676 | 66,819 |
| Interest Income | 3,336 | 3,336 |
| Interest Expense | $(3,155)$ | $(3,155)$ |
| Other Income, Net (e) | 3,123 | 3,123 |

Income from Continuing Operations Before Income Taxes
Provision for Income Taxes (f)
(a) Reported results were determined in accordance with U.S. generally accepted accounting principles (GAAP). Prior period amounts have been adjusted to reflect the treatment of Spectra-Physics as a discontinued operation.
(b) Adjusted results are non-GAAP measures and exclude charges to cost of revenues (note c), amortization of acquisition-related intangible assets, restructuring and other costs/income (note d), certain other income/expense (note e), the tax consequences of these items (note f) and results of discontinued operations.
(c) Reported results in 2004 include $\$ 2,408,000$ of charges primarily for the sale of inventories revalued at the date of acquisition.
(d) Reported results in 2005 include restructuring and other items consisting principally of severance, abandoned facility and other expenses of real estate consolidation and net gains on the sale of buildings. Reported results in 2004 include restructuring and other items consisting principally of severance, abandoned facility and other expenses of real estate consolidation, gain on the sale of a business and legal/advisory fees associated with a reorganization of the company's non-U.S. subsidiary structure.
(e) Reported results include $\$ 1,621,000$ of gains from the sale of shares of Thoratec Corporation in 2004.
(f) Adjusted provision for income taxes excludes $\$ 2,254,000$ and $\$ 2,253,000$ of incremental tax benefit in 2005 and 2004 , respectively, for the items in (b) through (e).

```
Segment Data (g)(h)(i)(l)
(In thousands except percentage amounts)
Life and Laboratory Sciences
    Revenues
    GAAP Operating Income
    Cost of Revenue Charges (j)
    Restructuring and Other Items (k)
    Amortization of Acquisition-related Intangible Assets
        Adjusted Operating Income
        GAAP Operating Margin
        Adjusted Operating Margin
Measurement and Control
    Revenues
    GAAP Operating Income
    Cost of Revenue Charges (j)
    Restructuring and Other Items (k)
    Amortization of Acquisition-related Intangible Assets
    Adjusted Operating Income
    GAAP Operating Margin
    Adjusted Operating Margin
Consolidated (including Corporate Costs)
    Revenues
    GAAP Operating Income
    Cost of Revenue Charges (j)
    Restructuring and Other Items (k)
    Amortization of Acquisition-related Intangible Assets
    Adjusted Operating Income
    GAAP Operating Margin
    Adjusted Operating Margin
```

(g) GAAP operating income and GAAP operating margin were determined in accordance with U.S. generally accepted accounting principles.
(h) Adjusted operating income and adjusted operating margin are non-GAAP measures and exclude the items in notes (c) and (d) and amortization of acquisition-related intangible assets.
(i) Depreciation expense in 2005 was $\$ 6,779,000$ at Life and Laboratory Sciences, $\$ 2,416,000$ at Measurement and Control and $\$ 10,152,000$ Consolidated. Depreciation expense in 2004 was $\$ 7,535,000$ at Life and

## Edgar Filing: THERMO ELECTRON CORP - Form 8-K

Laboratory Sciences, $\$ 2,457,000$ at Measurement and Control and $\$ 10,878,000$ Consolidated.
(j) Includes items described in note (c).
(k) Includes items described in note (d).
(l) Book-to-bill ratio was 1.01 in the first quarter of 2005.

Condensed Consolidated Balance Sheet (unaudited)

| (In thousands) | April 2, 2005 |  | Dec. |  |
| :---: | :---: | :---: | :---: | :---: |
| Current Assets: |  |  |  |  |
| Cash and cash equivalents | \$ | 351,560 |  |  |
| Short-term available-for-sale investments |  | 177,043 |  |  |
| Accounts receivable, net |  | 458,558 |  |  |
| Inventories |  | 345,605 |  |  |
| Other current assets |  | 152,852 |  |  |
|  |  | 485,618 |  |  |
| Property, Plant and Equipment, Net |  | 238,030 |  |  |
| Acquisition-related Intangible Assets |  | 166,305 |  |  |
| Other Assets |  | 159,171 |  |  |
| Goodwill |  | 505,339 |  |  |
|  | \$ | 554,463 |  |  |
| Current Liabilities: |  |  |  |  |
| Short-term obligations and current maturities of long-term obligations | \$ | 15,500 |  |  |
| Other current liabilities |  | 491,846 |  |  |
| Current liabilities of discontinued operations |  | 41,173 |  |  |
|  |  | 548,519 |  |  |
| Long-term Deferred Income Taxes and Other Long-term Liabilities |  | 105,524 |  |  |
| Long-term Obligations: |  |  |  |  |
| Senior notes |  | 133,681 |  |  |
| Subordinated convertible obligations |  | 77,234 |  |  |
| Other |  | 12,812 |  |  |
|  |  | 223,727 |  |  |
| Total Shareholders' Equity |  | 676,693 |  |  |
|  | \$ | 554,463 |  |  |


[^0]:    "To drive top-line growth, we continue to expand our portfolio of products and services, with a focus on creating integrated instrument solutions that allow our customers to make their processes more efficient. Our new LeadStream Solution(TM) featured at Pittcon, for example, is a suite of integrated instruments, robotics and software that eases a major bottleneck in drug discovery by improving the speed and accuracy of ADME/Tox screening. Our own innovations are enhanced by strategic acquisitions such as Kendro, which will greatly extend our laboratory offerings after its expected closing in the second quarter. The recent additions of Niton and R\&P (Rupprecht and Patashnick) further strengthen our position in industrial and environmental markets as well.
    "We expect our positive earnings momentum to continue in the second quarter of

